https://www.selleckchem.com/products/ab680.html
Preliminary results from the SABINA (SABA use IN Asthma) program showed lower overuse of short-acting β -agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA's results might have been affected by the Italian National Health System and pharmaceutical market dynamics, by examining patients' characteristics in relation to SABA prescription/purchase habits. Multiple approaches were used (1) a retrospective study using the General Practitioners' (GPs) Italian IQVIA Longitudi
Like
Comment
Share
